Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) - Investment analysts at Wedbush lowered their Q2 2025 EPS estimates for shares of Scholar Rock in a research note issued on Wednesday, May 14th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.66) per share for the quarter, down from their previous forecast of ($0.61). Wedbush currently has a "Outperform" rating and a $50.00 target price on the stock. The consensus estimate for Scholar Rock's current full-year earnings is ($2.42) per share. Wedbush also issued estimates for Scholar Rock's Q3 2025 earnings at ($0.64) EPS, Q4 2025 earnings at ($0.64) EPS, FY2025 earnings at ($2.61) EPS, Q1 2026 earnings at ($0.63) EPS, Q2 2026 earnings at ($0.58) EPS, Q3 2026 earnings at ($0.48) EPS, Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($2.04) EPS, FY2027 earnings at ($0.58) EPS and FY2028 earnings at $0.49 EPS.
Scholar Rock Stock Performance
Scholar Rock stock opened at $30.55 on Monday. The firm has a 50 day simple moving average of $31.19 and a 200-day simple moving average of $35.96. Scholar Rock has a 1-year low of $6.76 and a 1-year high of $46.98. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. The stock has a market cap of $2.90 billion, a price-to-earnings ratio of -13.00 and a beta of 0.37.
Scholar Rock (NASDAQ:SRRK - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same quarter last year, the firm earned ($0.59) EPS.
Hedge Funds Weigh In On Scholar Rock
A number of hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. boosted its position in shares of Scholar Rock by 1.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company's stock worth $310,000 after purchasing an additional 379 shares during the period. GF Fund Management CO. LTD. boosted its position in shares of Scholar Rock by 21.9% during the 1st quarter. GF Fund Management CO. LTD. now owns 2,396 shares of the company's stock worth $77,000 after purchasing an additional 430 shares during the period. CWM LLC boosted its position in shares of Scholar Rock by 152.8% during the 1st quarter. CWM LLC now owns 996 shares of the company's stock worth $32,000 after purchasing an additional 602 shares during the period. Amalgamated Bank boosted its position in shares of Scholar Rock by 30.6% during the 4th quarter. Amalgamated Bank now owns 2,643 shares of the company's stock worth $114,000 after purchasing an additional 620 shares during the period. Finally, Global Retirement Partners LLC boosted its position in shares of Scholar Rock by 584.7% during the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock worth $39,000 after purchasing an additional 766 shares during the period. Hedge funds and other institutional investors own 91.08% of the company's stock.
Insider Activity
In other news, insider Tracey Sacco sold 6,500 shares of the stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $33.08, for a total value of $215,020.00. Following the completion of the sale, the insider now owns 71,750 shares of the company's stock, valued at $2,373,490. This represents a 8.31% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Katie Peng sold 1,006 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $34.42, for a total transaction of $34,626.52. Following the completion of the sale, the director now directly owns 30,319 shares of the company's stock, valued at approximately $1,043,579.98. This trade represents a 3.21% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 255,231 shares of company stock valued at $9,220,236 in the last 90 days. Company insiders own 13.30% of the company's stock.
About Scholar Rock
(
Get Free Report)
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Scholar Rock, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scholar Rock wasn't on the list.
While Scholar Rock currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
